Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT Multi Medika Internasional Tbk's Debt-to-EBITDA or its related term are showing as below:
ISX:MMIX's Debt-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.185 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT Multi Medika Internasional Tbk Debt-to-EBITDA Related Terms
PT Multi Medika Internasional Tbk Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Multi Medika Internasional Tbk Debt-to-EBITDA Chart
PT Multi Medika Internasional Tbk Annual Data
Trend
Dec20
Dec21
Debt-to-EBITDA
N/A
0.01
PT Multi Medika Internasional Tbk Semi-Annual Data
Dec20
Dec21
Debt-to-EBITDA
N/A
0.01
PT Multi Medika Internasional Tbk Debt-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, PT Multi Medika Internasional Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Multi Medika Internasional Tbk Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Multi Medika Internasional Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Multi Medika Internasional Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (Dec. 2021) EBITDA data.
PT Multi Medika Internasional Tbk (ISX:MMIX) has a Debt-to-EBITDA of 0.01 as of Dec. 2021. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Multi Medika Internasional Tbk.
Is PT Multi Medika Internasional Tbk's Debt-to-EBITDA too high?
PT Multi Medika Internasional Tbk's current Debt-to-EBITDA is 0.01. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. PT Multi Medika Internasional Tbk's value of 0.01 is 99.5% below this industry median. Overall, PT Multi Medika Internasional Tbk has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does PT Multi Medika Internasional Tbk's Debt-to-EBITDA compare to competitors?
PT Multi Medika Internasional Tbk's Debt-to-EBITDA of 0.01 can be compared against companies in the Healthcare Providers & Services industry. The industry median Debt-to-EBITDA is 2.19. PT Multi Medika Internasional Tbk's value of 0.01 is 99.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Multi Medika Internasional Tbk's current Debt-to-EBITDA of 0.01 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Multi Medika Internasional Tbk. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Multi Medika Internasional Tbk's current Debt-to-EBITDA is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Multi Medika Internasional Tbk stock overvalued right now?
PT Multi Medika Internasional Tbk (ISX:MMIX) has a current Debt-to-EBITDA of 0.01. The current Debt-to-EBITDA is 0.01 and 99.5% below the Healthcare Providers & Services industry median of 2.19. PT Multi Medika Internasional Tbk's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT Multi Medika Internasional Tbk (ISX:MMIX), the current Debt-to-EBITDA is 0.01 as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Multi Medika Internasional Tbk is engaged in the wholesale trading of medical devices and pharmaceutical and laboratory equipment for humans, operating lease, and non-copyrighted works. It also wholesales other food and beverages, such as rice flour, tapioca flour, bakery premix, caramel, processed honey, shrimp crackers and others; agricultural food and beverages, such as herbs and spices; livestock and fisheries; non-alcoholic beverages, such as fruit juice, soft drinks, mineral water, bottled water, and other similar products; cosmetics for humans such as perfume, soap, powder and others. Its segments include Mask and other non food and beverages, and food and beverages. It derives the majoritf of the revenue from Mask and other non food and beverages segments.
24GF Score
Get the complete analysis for ISX:MMIX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:MMIX has been successfully added to your 
